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Abstract
OBJECTIVES: The SYNTAX score II (SSII) was developed from the SYNTAX trial to predict the 4-year all-cause mortality after left main or
multivessel disease revascularization and to facilitate the decision-making process. The SSII provides the following treatment recommen-
dations: (i) coronary artery bypass grafting (CABG) or percutaneous coronary intervention (PCI) (equipoise risk), (ii) CABG preferred (exces-
sive risk for PCI) or (iii) PCI preferred (excessive risk for CABG). We sought to externally validate SSII and to investigate the impact of not
abiding by the SSII recommendations in the randomized EXCEL trial of PCI versus CABG for left main disease.
METHODS: The calibration plot of predicted versus observed 4-year mortality was constructed from individual values of SSII in EXCEL. To
assess overestimation versus underestimation of predicted mortality risk, an optimal fit regression line with slope and intercept was deter-
mined. Prospective treatment recommendations based on SSII were compared with actual treatments and all-cause mortality at 4 years.
RESULTS: SSII variables were available from EXCEL trial in 1807/1905 (95%) patients. For the entire cohort, discrimination was possibly
helpful (C statistic = 0.670). SSII-predicted all-cause mortality at 4 years overestimated the observed mortality, particularly in the highest-
risk percentiles, as confirmed by the fit regression line [intercept 2.37 (1.51–3.24), P = 0.003; slope 0.67 (0.61–0.74), P < 0.001]. When the
SSII-recommended treatment was CABG, randomized EXCEL patients treated with PCI had a trend towards higher mortality compared
with those treated with CABG (14.1% vs 5.3%, P = 0.07) in the as-treat population. In the intention-to-treat population, patients randomized
to PCI had higher mortality compared with those randomized to CABG (15.1% vs 4.1%, P = 0.02), when SSII recommended CABG.
CONCLUSIONS: In the EXCEL trial of patients with left main disease, the SSII-predicted 4-year mortality overestimated the 4-year
observed mortality with a possibly helpful discrimination. Non-compliance with SSII CABG treatment recommendations (i.e. randomized
to PCI) was associated with higher 4-year all-cause mortality.
Keywords: Coronary artery bypass grafting • Left main coronary artery disease • Drug-eluting stents • SYNTAX score
ABBREVIATIONS
3VD 3-Vessel disease
CABG Coronary artery bypass grafting
CI Confidence interval
EXCEL Evaluation of XIENCE vs Coronary Artery Bypass
Grafting for Effectiveness of Left Main
Revascularization
HR Hazard ratio
ITT Intention-to-treat
LM Left main
PCI Percutaneous coronary intervention
RCTs Randomized controlled trials
SS SYNTAX score
SSII SYNTAX score II
SYNTAX Synergy between PCI with Taxus and Cardiac Surgery
INTRODUCTION
The anatomical Synergy between PCI with Taxus and Cardiac
Surgery (SYNTAX) score (SS) is a practical tool that uses coronary
anatomy to objectively guide the decision-making process for
revascularization treatment in patients with complex coronary
artery disease [left main (LM) disease or 3-vessel disease (3VD)]
[1, 2]. Studies have demonstrated the utility of the anatomical SS
to help guide selection of revascularization mode between cor-
onary artery bypass grafting (CABG) and percutaneous coronary
intervention (PCI) [3–5], and it is therefore advocated by contem-
porary guidelines [6–8].
The SYNTAX score II (SSII) was subsequently developed from
the SYNTAX trial to further improve decision-making between
CABG and PCI in patients with complex coronary artery disease
[9]. The SSII combines anatomic and clinical factors, allowing for
more individualized decision-making between PCI and CABG.
The SSII gives a clear recommendation based on the predicted 4-
year mortality for both CABG and PCI: (i) CABG only; (ii) PCI
only; or (iii) equipoise, meaning the mortality risk is equal for PCI
and CABG. SSII has been externally validated in 2 real-world
registries [9, 10] and in pooled randomized trial populations
[11, 12].
As recommended by the guidelines, heart teams should indi-
cate the best revascularization treatment for patients with 3VD
and LM disease based on anatomy and clinical conditions [13]. In
the single-arm SYNTAX II study, outcomes of patients with com-
plex coronary artery disease undergoing PCI were compared
with a historical surgical comparator matched by similar SSII [14,
15]; however, randomized clinical trials (RCTs) assessing revascu-
larization strategies (PCI or CABG) for 3VD or LM performed to
date have not taken into account integrated risk score recom-
mendation such as that from the SSII. As such, RCTs have
assigned patients to PCI in whom SSII may have otherwise rec-
ommended CABG and vice-versa. Thus, RCTs may be uniquely
suited for assessing the mortality impact associated with the lack
of concordance between SSII recommendations and actual treat-
ment. We therefore sought to externally validate SSII and to de-
termine the mortality impact of not abiding by the SSII
recommendations in the setting of a large-scale contemporary
RCT comparing PCI and CABG for the treatment of LM stem
disease.
METHODS
Trial design and study population
The present study is a post-hoc analysis of patients randomized
to CABG or PCI in the EXCEL (Evaluation of XIENCE vs Coronary
Artery Bypass Grafting for Effectiveness of Left Main
Revascularization) trial [16]. The EXCEL trial methodology and
main results have been previously published [16]. Briefly, EXCEL
was an international, open-label, multicentre randomized trial
that compared PCI with everolimus-eluting stents with CABG in
patients with LM disease and an investigator-reported anatomical
SS <_32 (i.e. low or intermediate). Eligible patients (n = 1905),
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recruited from 2010 to 2014, were assigned to undergo either
PCI with everolimus-eluting stents (XIENCE, Abbott Vascular,
Santa Clara, CA, USA, n = 948) or CABG (n = 957). Key inclusion
criteria were LM stenosis >_70% by visual estimation or haemo-
dynamically significant stenosis of 50% to <70% by either invasive
or non-invasive testing. All patients were considered by a local
heart team to be suitable for revascularization with either PCI or
CABG. Calibration and discrimination were assessed in the as-
treated population. Guideline-directed medical therapy was rec-
ommended for all patients. The trial was conducted in accord-
ance with ethical principles for medical research involving
human subjects of the World Medical Association (Declaration of
Helsinki). Its protocol was approved by the ethics committee at
each participating centre, and all patients signed informed con-
sent. Follow-up is ongoing through 5 years, with all patients hav-
ing completed 4-year follow-up at the time of this report.
The SYNTAX score II
The SSII has been previously described [9]. Briefly, it combines
data from the coronary anatomy (anatomical SS and the pres-
ence of unprotected LM disease) with clinical characteristics (sex,
age, creatinine clearance, left ventricular ejection fraction, chron-
ic obstructive pulmonary disease and peripheral vascular disease)
allowing for 4-year all-cause mortality predictions to be made
following revascularization with either CABG or PCI. Based on
treatment effect interactions for PCI and CABG, the SSII provides
different scores with their correspondent estimated mortalities
for each of the revascularization strategies. Thus, patients are rec-
ommended for CABG if the predicted mortality for PCI is statis-
tically higher (with 95% of confidence), and likewise are
recommended for PCI if the predicted risk of mortality following
CABG is higher (with 95% of confidence). If the predicted mortal-
ity rates are not statistically different between PCI and CABG,
patients are recommended for either treatment (equipoise risk).
In summary, SSII affords a personalized recommendation for: (i)
only CABG; (ii) only PCI; or (iii) equipoise between CABG and
PCI. In the EXCEL trial, the anatomic SS was measured at an inde-
pendent angiographic core laboratory (Cardiovascular Research
Foundation, New York, NY, USA) [17]. The core laboratory-
assessed SS measures were used for the SSII calculation given the
tendency of sites to under-estimate the anatomic SS [2, 17, 18].
End points
The primary end point in the present study was all-cause mortal-
ity at 4 years, the measure for which the SSII was developed and
validated. Mortality was confirmed by an independent Clinical
Events Committee by review of original source documents.
Statistical analysis
Continuous data are presented as mean ± standard deviation or
median and interquartile range and were compared with the
Student’s t-test or Wilcoxon rank sum test as appropriate.
Categorical data are presented as percentages (counts) and were
compared with the v2 test or Fisher’s exact test. Clinical event
rates are presented as Kaplan–Meier estimates in time-to-first-
event analyses and were compared with the log-rank test.
Calibration between observed and expected mortality at 4 years
based on SSII was investigated in quintiles of the EXCEL popula-
tion. A linear regression model was fit between observed and
predicted all-cause mortality in each quintile, and the intercept,
slope and R2 from the model result were determined.
Discrimination was assessed using C statistics, also represented
by the receiver-operating characteristic curve (since the outcome
is binary), and using the Brier score [19, 20]. Calibration was eval-
uated using the Hosmer–Lemeshow goodness-of-fit test. The
Kaplan–Meier method was used to estimate the cumulative rates
of clinical events in the quintiles. Cox proportional-hazards re-
gression models were used to calculate hazard ratios (HRs) in the
subgroups based on SSII score recommendation and to test for
interactions. If the assumptions were not satisfied, a logistic re-
gression was performed and the odds ratios with its 95% confi-
dence interval (CI) reported along. All analyses to test the impact
of not abiding by the SSII recommendation were performed
according to the: (i) randomization of the patients (intention-to-
treat population—ITT) to either CABG or PCI and (ii) treatment
that the patients actually received (PCI or CABG)—i.e. the as-
treated population; and results are presented for both popula-
tions. A 2-sided P-value of 0.05 or less was considered to indicate
statistical significance. All statistical analyses were performed
using SAS version 9.4 (SAS Institute, Cary, NC, USA).
RESULTS
Discrimination and calibration
Out of the 1905 patients randomized in EXCEL, 1807 had all the
variables for the retrospective calculation of SSII, representing
the present study population. Within 4 years, 156 patients died
(Kaplan–Meier estimated rate 8.9%). The calibration plot for the
observed versus expected overall 4-year mortality rates is pre-
sented in Fig. 1. The C statistic for the SSII prediction for the
Figure 1: Flexible calibration plot of observed versus SYNTAX score II predicted
4-year mortality of the entire population from the EXCEL trial with available
SYNTAX score II measures. Red line represents the identity line.
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entire EXCEL population was 0.670 (95% CI 0.624–0.715,
P < 0.0001), which is considered a possibly helpful discrimination.
The fit regression line showed a slope of 0.67 (95% CI 0.61–0.74,
P = 0.0006) and intercept of 2.37 (95% CI 1.51–3.24, P = 0.0031).
The slope of <1 with a positive intercept evidences the overesti-
mation of the prediction model in the higher scores and under-
estimation in the lower scores. The Brier score for the prediction
was 0.077. A Brier score of zero would represent a perfect model,
whereas a score of 0.25 is considered non-informative [19, 20].
Model calibration was good (v2 = 8.56; PHL = 0.38).
The median (interquartile range) SSII measure of randomized
patients undergoing PCI versus CABG in EXCEL was 28.47 (23.41–
35.57) versus 31.10 (25.00–37.40), respectively, P = 0.0006. In this
population, by 4 years 92 and 64 PCI and CABG patients had died,
respectively (Kaplan–Meier estimated rates of 10.26% and 7.40%).
The C statistic (95% CI) for SSII prediction of 4-year mortality after
PCI was 0.661 (0.600–0.721) and the C statistic for CABG was
0.695 (0.628–0.762), and model calibration was good for each
(v2 = 6.68; PHL = 0.57 and v
2 = 7.05; PHL = 0.53, respectively).
Concordance and discordance with the SYNTAX
score II recommendation
Among the 1807 study patients, SSII recommended ‘PCI only’ in
342 patients (18.9%), ‘CABG only’ in 159 (8.8%) and ‘CABG or PCI’
in 1306 patients (72.3%). Baseline characteristics and medication
intake in each SSII recommendation group are shown in the
Supplementary Material. CABG was performed in 184/342
(52.9%) patients in whom SSII recommended PCI only, and PCI
was performed in 81/159 (50.9%) patients in whom SSII recom-
mended CABG only (Fig. 2). The actual treatment was thus at vari-
ance (discordant) with the SSII recommendation in 265/1807
patients (14.7%). If the SSII recommendation was for ‘PCI or
CABG’, there was no difference in mortality at 4 years if the patient
received either treatment (9.0% for PCI vs 7.5% for CABG, HR
1.19, 95% CI 0.81–1.75; P = 0.37). If the SSII recommendation was
‘PCI only’, 4-year mortality was also not significantly different in
patients treated with PCI versus CABG (13.6% for PCI vs 7.8% for
CABG, HR 1.72, 95% CI 0.88–3.39; P = 0.11/odds ratio 1.86, 95% CI
0.91–3.80; P = 0.09); however, if the SSII recommendation was to
undergo ‘CABG only’, the 4-year rate of all-cause death was higher
in those treated with PCI compared with those undergoing CABG
(14.1% vs 5.3%, HR 2.74, 95% CI 0.87–8.61; P = 0.07, respectively)
(Fig. 3). In order to use an ‘unbiased’ population, we performed
the same analysis on the ITT population, i.e. patients grouped as
they were randomized. In the ITT population, in patients with an
SSII recommendation ‘PCI only’, 4-year mortality was not signifi-
cantly different between patients randomized to PCI versus CABG
(13.7% for PCI vs 8.2% for CABG, P = 0.14); however, in patients
with an SSII recommendation ‘CABG only’, the 4-year rate of all-
cause death was significantly higher in those randomized to PCI
compared with those randomized to CABG (15.1% vs 4.1%,
P = 0.02, respectively) (Fig. 3 and Supplementary Figure 1).
DISCUSSION
The main findings of the present study are as follows: (i) The SSII
has now been externally validated in a randomized population
Figure 2: Flow of the patients in the EXCEL trial. From top down—the calculation of the SSII and its personalized recommendation. From bottom up—the randomiza-
tion process of the trial. The blue lines show the path of patients who received a treatment concordant with the SSII recommendation. Red dashed lines show the
path of patients who received a treatment other than the one recommended by the SSII. CABG: coronary artery bypass grafting; PCI: percutaneous coronary interven-
tion; SSII: SYNTAX score II.
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Figure 3: Time-to-event curves for all-cause death. (A–C) Refers to the intention-to-treat population and (D–E) refers to the as-treated population. (A) Shows the
patients who received a SYNTAX score II (SSII) recommendation to undergo CABG and were randomized to PCI (blue line) or CABG (red line). (B) Shows the patients
who received an SSII recommendation to undergo PCI and were randomized to PCI (blue line) or CABG (red line). (C) Shows the patients who received an SSII recom-
mendation of equipoise risk (CABG or PCI) and were randomized to PCI (blue line) or CABG (red line). (D) Shows the patients who received an SSII recommendation
to undergo CABG and underwent PCI (blue line) versus CABG (red line). (E) Shows the patients who received an SSII recommendation to undergo PCI and underwent
PCI (blue line) versus CABG (red line). (F) Shows the patients who received an SSII recommendation of equipoise risk (CABG or PCI) and underwent PCI (blue line) ver-
sus CABG (red line). CABG: coronary artery bypass grafting; CI: confidence interval; HR: hazard ratio; PCI: percutaneous coronary intervention.
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with LM disease, demonstrating possibly helpful discrimination
(C statistic = 0.670) and good calibration; (ii) non-respect of the
SSII treatment recommendation for CABG in the EXCEL trial (i.e.
performance of PCI instead) was associated with a trend towards
greater mortality compared with performance of CABG as rec-
ommended; and (iii) no significant differences in 4-year mortality
between PCI and CABG were observed when the SII recommen-
dation was to perform PCI or noted equipoise between PCI and
CABG.
The present study is the first to validate the SSII in a random-
ized LM disease population for the performance of CABG versus
PCI, and the results are in keeping with the original validation
upon development of SSII [9]. The internal validation of SSII in
the index SYNTAX trial [1] showed a C statistic of 0.725, whereas
the external validation performed in the DELTA registry [21] co-
hort of non-randomized patients resulted in a C statistic of
0.716—both possibly helpful and somewhat similar to what we
observed in the randomized EXCEL population (0.670).
The current 4-year data from the EXCEL trial allow for the first
time a proper validation of the discrimination ability of the SSII.
With regard to definition, discrimination is considered outstand-
ing if C statistic >_0.9, excellent if >_0.8 and <0.9, acceptable if >_0.7
and <0.8, poor if >0.5 and <0.7 and absent if C statistic = 0.5 [22].
In a more recent definition, a C statistic <0.60 defines a poor dis-
crimination, 0.60–0.75 a possibly helpful discrimination and
>0.75 a clearly useful discrimination [23].Therefore, our results
can define the discrimination ability of SSII as poor or possibly
helpful.
Worthy of mentioning from our analysis is the overestimation
of 4-year mortality from that predicted in SSII and observed in
EXCEL, particularly in the highest quintile of predicted mortality
(Fig. 1). The likely explanation for this discordance is the fact that
SSII was developed in an earlier period at the time of the
SYNTAX trial. In this regard we have previously shown that there
has been an improvement in surgical outcomes from SYNTAX to
EXCEL [24]. As to PCI, the stent used in the SYNTAX trial was the
first-generation paclitaxel-eluting thick-strut TAXUS stent. In
EXCEL, the second-generation everolimus-eluting XIENCE stent
was used, which has thinner struts and a more biocompatible
polymer and drug, resulting in improved late outcomes [14].
The SSII was created to fulfil the need for objective and indi-
vidualized guidance for decision-making between PCI and CABG
in patients with complex coronary artery disease [9]. The heart
team concept is currently the proper approach for such patients,
and non-compliance to guidelines may result in inappropriate
revascularization [13, 25, 26]. It has been previously demon-
strated that applying the SSII affords high agreement with heart
team revascularization decisions [27]. The present study is the
first to demonstrate a potential harmful effect of not complying
with the SSII recommendation. Interestingly this negative effect
was largely confined to the CABG recommendation, i.e. when the
patient was referred to PCI even though there was a clear SSII
recommendation for CABG (Fig. 3). In such cases a sustained sep-
aration of the Kaplan–Meier curves was evident favouring CABG.
Paradoxically, a trend favouring surgery was also observed when
the recommendation was for the patient to undergo PCI, al-
though it was statistically not different.
Another important message arising from these data is that
when the recommendation derived from SSII was for ‘CABG or
PCI’ (i.e. equipoise was present), the 4-year mortality rates for ei-
ther CABG or PCI were indeed equivalent (P = 0.37). Worthy of
note for the heart teams evaluating LM disease patients is that
the observed mortality rates of patients undergoing CABG was
similar in those with an SSII recommendation for ‘PCI only’ com-
pared with an SSII recommendation for ‘CABG or PCI’. Thus,
even if a patient has a PCI recommendation, the heart team
could choose CABG based on other clinical reasons (e.g. doubtful
dual antiplatelet therapy adherence) without apparent impact on
4-year mortality.
In the single-arm SYNTAX II study, the anatomical recommen-
dation of the European Society of Cardiology (ESC) was not
applied; however, the ethical aspect of the recommendation
treatment was maintained since the patient could only be
included if the SSII recommendation was for equipoise (‘CABG or
PCI’). This was accomplished by an exploratory comparison of
the PCI population with the surgical cases of the original SYNTAX
trial using only a population matched for the SSII, which resulted
in similar event rates [14].
Limitations
This study has limitations inherent in a non-prespecified retro-
spective analysis. A prospective analysis of the predictive ability
of SSII would be preferred. Nevertheless, the fact that we
assessed patients who were randomized without considering the
SSII recommendation was a strength for the present analysis, as it
allowed us to assess the impact of non-compliance to the SSII
treatment recommendation. In addition, it would be unethical to
assign a patient to a treatment arm with the belief that, by the
SSII prediction, the patient would have worse outcomes. Of note,
in the present study of patients with LM disease the SSII recom-
mended ‘CABG only’ in only 8.8% of patients; however, patients
with a site-assessed anatomical SS >32 were excluded from ran-
domization in the EXCEL trial. By core lab analysis 25% of
enrolled patients had, in fact, an anatomical SS >32. Nonetheless,
further studies are required to validate the SSII in patients with
high anatomic SS in whom CABG is more frequently recom-
mended. Despite the numerically higher all-cause 4-year mortal-
ity in patients receiving PCI amongst those with ‘CABG only
recommendation by SSII’ (as-treated population), the CI for the
HR was wide thus not allowing for a better conclusion to be
drawn on the effect of undergoing PCI in discordance with the
SSII recommendation. Nevertheless, when analysing the ‘un-
biased’ ITT population, the mortality was significantly higher
when performing PCI, instead of the recommended CABG.
Finally, the SSII was developed for patients with 3VD and/or LM
disease from the SYNTAX trial, whereas the present study was
restricted to the treatment of LM disease with or without add-
itional diseased vessels.
CONCLUSIONS
For patients with LM disease enrolled in the EXCEL trial, the pre-
dicted 4-year mortality based on the SSII overestimated the
4-year observed mortality, with possibly helpful overall discrim-
ination. Non-compliance with the SSII recommendation to
undergo CABG (i.e. treating the patient with PCI—as-treated
population) was associated with a trend towards higher 4-year
all-cause mortality, i.e. a numerically large difference that did not
reach statistical significance, whereas, in the ITT population, ran-
domization of patients to PCI in discordance with the SSII recom-
mendation (CABG only) resulted in significantly higher 4-year
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all-cause mortality as compared with patients randomized to
CABG. These results are merely hypothesis-generating due to the
small sample size of the population with discordance in recom-
mendation/treatment. Additional larger studies involving patients
with multivessel disease with or without LM involvement are
warranted for more conclusive findings on the harmful effect of
not abiding by the SYNTAX II recommendation.
SUPPLEMENTARY MATERIAL
Supplementary material is available at EJCTS online.
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